# A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.

> PubMed lists PMID 42713641 in NEJM evidence as Journal Article, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42713641-vosoritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-09
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42713641-vosoritide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42713641-vosoritide-v1.json
- Content SHA-256: `f2d4f52dfb733ef76cfa52434feb521687e0d3cf0a9d7acb9d0bb66f1c3bada5`

## Claims and source pins

### Headline

A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia. ([`pubmed-observation-pmid-42713641-2026-09-09-3296b303c913`](#source-pubmed-observation-pmid-42713641-2026-09-09-3296b303c913))

### Summary

PubMed lists PMID 42713641 in NEJM evidence as Journal Article, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42713641-2026-09-09-3296b303c913`](#source-pubmed-observation-pmid-42713641-2026-09-09-3296b303c913))

### Paragraph 1

PubMed lists PMID 42713641 in NEJM evidence as Journal Article, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42713641-2026-09-09-3296b303c913`](#source-pubmed-observation-pmid-42713641-2026-09-09-3296b303c913))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42713641-2026-09-09-3296b303c913`](#source-pubmed-observation-pmid-42713641-2026-09-09-3296b303c913))

## Sources

<a id="source-pubmed-observation-pmid-42713641-2026-09-09-3296b303c913"></a>
- **A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia. · retained source version 1:2026-09-09:current:3296b303c9139f7f941f253495615824e23db2faf2f9883190a3e6c174b16ec4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42713641/) (`pubmed-observation-pmid-42713641-2026-09-09-3296b303c913`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42713641-vosoritide-v1.json SHA-256: f2d4f52dfb733ef76cfa52434feb521687e0d3cf0a9d7acb9d0bb66f1c3bada5.